Urologic malignancy risk with chronic tumor necrosis factor-alpha inhibitor (TNF-I) exposure: a multicenter, retrospective cohort study - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Risk of Urologic Cancers Associated with Long-term Use of Tumor Necrosis Factor-alpha Inhibitors: A Multicenter Retrospective Analysis

  • By

  • Conor B. Driscoll

  • Jordan M. Rich

  • Christopher Yang

  • Joseph Nicolas

  • Dylan Isaacson

  • Philip Silberman

  • Xinlei Mi

  • Sai Kaushik Shankar Ramesh Kumar

  • Hui Zhang

  • Steven Belknap

  • William H. Temps

  • Edward M. Schaeffer

  • Shilajit D. Kundu

  • February 26, 2026

Share

Original Source(s)

Urologic malignancy risk with chronic tumor necrosis factor-alpha inhibitor (TNF-I) exposure: a multicenter, retrospective cohort study

  • by Conor B. Driscoll, Jordan M. Rich, Christopher Yang, Joseph Nicolas, Dylan Isaacson, Philip Silberman, Xinlei Mi, Sai Kaushik Shankar Ramesh Kumar, Hui Zhang, Steven Belknap, William H. Temps, Edward M. Schaeffer, Shilajit D. Kundu

  • February 26, 2026

Related Content

ECP 2026: Epidermal Biomarker Resolves Tricky Skin Lesions

Study investigates the diagnostic utility of epidermal CD271 IHC expression in challenging melanocytic lesions

  • September 18, 2026

  • 3 min
Nirsevimab may curb RSV severity

Real-world estimates showed protection across emergency, inpatient, and intensive care settings during Canada’s first universal immunization season.

Roving Reporter Asks: How Is Cell and Gene Therapy Manufacturing Becoming More Scalable?

IBTV speaks with industry leaders at ASGCT 2026 about the technologies, processes, and manufacturing strategies helping advanced therapies progress toward commercial scale

  • September 18, 2026

  • 2 min